BLSM
HOLD / NEUTRALNeutralComposite
47.10
Technical
46.10
Fundamental
47.70
Rank
—
Price
15.99
Hurst
—
As of
Aug 11, 2026
Daily
BlossomHill Therapeutics, Inc.
HealthcareBiotechnologyBlossomHill Therapeutics is a clinical-stage drug developer focused on creating small molecule treatments for cancer. The company's lead candidates include BH-30643, targeting advanced lung cancer with EGFR mutations, and BH-30236, a CLK inhibitor being tested in patients with treatment-resistant blood cancers including acute myeloid leukemia and myelodysplastic syndrome. Founded in 2020 and headquartered in San Diego, the company operates in the biopharmaceutical sector.
Market cap
$437.0M
P/E (trailing)
—
P/E (forward)
-3.48
PEG ratio
—
Dividend yield
0.00%
Beta
—
52w range
12.93 – 27.99
Return on equity
—
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 13.75 (-14.1%) · range 13.75–26.82
Cycle position
14/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 98 · STRONG SETUP · exit proximity 0
Conviction
55/ 100 · maturity 0%
Buildup.338
EMA entry setup.4298
Fundamentals.2548
Volume profile
POC
16.39
Price vs POC
-16.1%
Overhead supply
98%
Runway
+14.8%
Value area 13.53–20.46 · 98% of 60d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +33.17% | +38.80% | mature |
| 40d | +0.54% | +62.35% | mature |